GSK focused on split as cost checks, COVID-19 easings aid earnings
The Peninsula
Plans for GSK to split in two are "well underway" it said on Wednesday, as a cost clampdown and rising clinic visits for critical treatments after an easing of COVID-19 curbs helped it land better-than-forecast first-quarter earnings.
GSK, which trails competitors in the coronavirus vaccines race, is under the microscope after a report that U.S. activist investor Elliott built up a significant stake. The British drugmaker said it would give details on June 23 on its plan to separate next year into an over-the-counter business and another for prescription drugs and vaccines.More Related News